Alexander E. Kuta Ph.D.
Net Worth
Last updated:
What is Alexander E. Kuta Ph.D. net worth?
The estimated net worth of Dr. Alexander E. Kuta Ph.D. is at least $7,843,917 as of 7 Mar 2023. He owns shares worth $1,381,022 as insider, has earned $2,547,415 from insider trading and has received compensation worth at least $3,915,480 in uniQure N.V..
What is the salary of Alexander E. Kuta Ph.D.?
Dr. Alexander E. Kuta Ph.D. salary is $652,580 per year as Executive Vice President of Quality & Regulatory in uniQure N.V..
How old is Alexander E. Kuta Ph.D.?
Dr. Alexander E. Kuta Ph.D. is 65 years old, born in 1960.
What stocks does Alexander E. Kuta Ph.D. currently own?
As insider, Dr. Alexander E. Kuta Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| uniQure N.V. (QURE) | Executive Vice President of Quality & Regulatory | 90,381 | $15.28 | $1,381,022 |
What does uniQure N.V. do?
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Alexander E. Kuta Ph.D. insider trading
uniQure N.V.
Dr. Alexander E. Kuta Ph.D. has made 35 insider trades between 2019-2023, according to the Form 4 filled with the SEC. Most recently he sold 585 units of QURE stock worth $12,496 on 7 Mar 2023.
The largest trade he's ever made was exercising 27,358 units of QURE stock on 28 Jul 2022. As of 7 Mar 2023 he still owns at least 90,381 units of QURE stock.
uniQure N.V. key executives
uniQure N.V. executives and other stock owners filed with the SEC:
- Dr. Alexander E. Kuta Ph.D. (65) Executive Vice President of Quality & Regulatory
- Dr. Ricardo Dolmetsch Ph.D. (56) Pres of R&D
- Mr. Christian Klemt (52) Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site
- Mr. Matthew Craig Kapusta (53) Chief Executive Officer & Executive Director